Lee Razalan
Family Medicine · Long Beach, CANPI 1780601534
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 332 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 11.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,704 and has fallen 76.0% since, to $410 in 2025. Among family medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 332 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$836
- AstraZeneca$821
- Novo Nordisk$783
- Bayer$752
- GSK$729
- Johnson & Johnson$488
- plus $3K from 20 others
What the payments were for
- Food & beverage$7,104100%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 45 | $836 |
| AstraZeneca(2 entities) | 33 | $821 |
| Novo Nordisk | 46 | $783 |
| Bayer | 41 | $752 |
| GSK | 24 | $729 |
| Johnson & Johnson | 23 | $488 |
| Amarin Pharma, Inc. | 19 | $444 |
| Lilly USA, LLC | 23 | $442 |
| Boehringer Ingelheim | 10 | $288 |
| Astellas Pharma US Inc | 12 | $257 |
| Exact Sciences | 10 | $245 |
| Merck | 11 | $180 |
| Amgen(2 entities) | 7 | $173 |
| Urovant Sciences Inc | 1 | $124 |
| Abbott | 5 | $102 |
| Novartis | 4 | $101 |
| Hikma Pharmaceuticals USA | 4 | $72 |
| Dexcom, Inc. | 3 | $65 |
| Biohaven Pharmaceuticals, Inc. | 2 | $52 |
| Lexicon Pharmaceuticals, Inc. | 1 | $34 |
| Gilead | 2 | $33 |
| E.r. Squibb & Sons, L.L.C. | 2 | $29 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,123 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 81 | $78,767 |
| JardianceEmpagliflozin | 43 | $58,213 |
| KerendiaFinerenone | 40 | $39,861 |
| EliquisApixaban | 30 | $37,015 |
| RybelsusSemaglutide | 26 | $26,180 |
| TradjentaLinagliptin | 25 | $23,861 |
| JanuviaSitagliptin Phosphate | 20 | $17,507 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $13,449 |
| MounjaroTirzepatide | 11 | $10,652 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 18 | $10,541 |
| Febuxostat | 36 | $6,747 |
| GlyxambiEmpagliflozin/Linagliptin | 11 | $6,300 |
| EntrestoSacubitril/Valsartan | 16 | $6,117 |
| Losartan Potassium | 356 | $4,328 |
| Atorvastatin Calcium | 386 | $3,669 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $821 | $89,30899 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $288 | $88,37479 claims |
| BayerKerendia | $752 | $39,86140 claims |
| PfizerEliquis | $836 | $37,01530 claims |
| Novo NordiskRybelsus | $783 | $26,18026 claims |
| MerckJanuvia | $180 | $17,50720 claims |
| GSKTrelegy Ellipta | $729 | $13,44921 claims |
| Lilly USA, LLCMounjaro | $442 | $10,65211 claims |
| NovartisEntresto | $101 | $6,11716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Long Beach
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
- Amira AyadBakersfield$360K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.